STRO
Sutro Biopharma, Inc.
NASDAQ · Healthcare · Biotechnology · US
$20.07
−2.29%0
Insider buys (3m)
0
Insider sells (3m)
$0.00
Net value (3m)
-22.4%
Price return (3m)
Form 4 filings
| Date | Insider | Activity | Shares | Price |
|---|---|---|---|---|
| Jun 9, 2026 | Lobacki Joseph M · director | A-Award | 10,000 | $26 |
| Jun 9, 2026 | Dybbs Michael · director | A-Award | 10,000 | $26 |
| Jun 9, 2026 | Jagpal Sukhi · director | A-Award | 10,000 | $26 |
| Jun 9, 2026 | Petree Daniel H · director | A-Award | 10,000 | $26 |
| Jun 9, 2026 | MATSUI CONNIE · director | A-Award | 10,000 | $26 |
| Jun 9, 2026 | PANEK JAMES P · director | A-Award | 10,000 | $26 |
| Jun 9, 2026 | Wigginton Jon Marc · director | A-Award | 10,000 | $26 |
| Jun 9, 2026 | Hunter Heidi · director | A-Award | 10,000 | $26 |
| Jun 2, 2026 | Chow Gregory K. · officer: CFO | M-Exempt | 2,500 | $0.00 |
| Mar 6, 2026 | Pauling David · officer: Chief Admin. Ofcr. & GC | M-Exempt | 675 | $0.00 |
| Mar 6, 2026 | Chung Jane · director, officer: Chief Executive Officer | M-Exempt | 788 | $0.00 |
| Mar 6, 2026 | Chung Jane · director, officer: Chief Executive Officer | F-InKind | 282 | $21 |
| Mar 6, 2026 | Pauling David · officer: Chief Admin. Ofcr. & GC | F-InKind | 277 | $21 |
| Mar 3, 2026 | Chung Jane · director, officer: Chief Executive Officer | A-Award | 175,000 | $21 |
| Mar 3, 2026 | Chung Jane · director, officer: Chief Executive Officer | M-Exempt | 688 | $0.00 |
| Mar 3, 2026 | Pauling David · officer: Chief Admin. Ofcr. & GC | A-Award | 33,600 | $21 |
| Mar 3, 2026 | Gerber Hans-Peter · officer: CHIEF SCIENTIFIC OFFICER | M-Exempt | 1,125 | $0.00 |
| Mar 3, 2026 | Chung Jane · director, officer: Chief Executive Officer | M-Exempt | 7,750 | $0.00 |
| Mar 3, 2026 | Gerber Hans-Peter · officer: CHIEF SCIENTIFIC OFFICER | A-Award | 5,000 | $0.00 |
| Mar 3, 2026 | Pauling David · officer: Chief Admin. Ofcr. & GC | F-InKind | 551 | $20 |
| Mar 3, 2026 | Chung Jane · director, officer: Chief Executive Officer | M-Exempt | 2,500 | $0.00 |
| Mar 3, 2026 | Chow Gregory K. · officer: CFO | A-Award | 5,000 | $0.00 |
| Mar 3, 2026 | Pauling David · officer: Chief Admin. Ofcr. & GC | A-Award | 4,200 | $0.00 |
| Mar 3, 2026 | Pauling David · officer: Chief Admin. Ofcr. & GC | M-Exempt | 500 | $0.00 |
| Mar 3, 2026 | Pauling David · officer: Chief Admin. Ofcr. & GC | M-Exempt | 2,356 | $0.00 |
| Mar 3, 2026 | Gerber Hans-Peter · officer: CHIEF SCIENTIFIC OFFICER | M-Exempt | 2,843 | $0.00 |
| Mar 3, 2026 | Chung Jane · director, officer: Chief Executive Officer | F-InKind | 1,271 | $20 |
| Mar 3, 2026 | Pauling David · officer: Chief Admin. Ofcr. & GC | M-Exempt | 842 | $0.00 |
| Mar 3, 2026 | Chung Jane · director, officer: Chief Executive Officer | A-Award | 40,000 | $0.00 |
| Mar 3, 2026 | Gerber Hans-Peter · officer: CHIEF SCIENTIFIC OFFICER | A-Award | 40,000 | $21 |
Institutional positioning
13F filings over the trailing two quarters
New 26Increased 22Reduced 15Sold out 70
| Filer | Action | Shares | Filed |
|---|---|---|---|
| BVF INC/IL | New Position | 1,251,788 | May 15, 2026 |
| AFFINITY ASSET ADVISORS, LLC | Increased | 1,069,519 | May 14, 2026 |
| SAMSARA BIOCAPITAL, LLC | Increased | 1,062,872 | May 15, 2026 |
| KYNAM CAPITAL MANAGEMENT, LP | Increased | 872,558 | May 15, 2026 |
| ORBIMED ADVISORS LLC | New Position | 801,144 | May 15, 2026 |
| VANGUARD CAPITAL MANAGEMENT LLC | New Position | 720,442 | May 15, 2026 |
| PERCEPTIVE ADVISORS LLC | New Position | 715,307 | May 29, 2026 |
| RA CAPITAL MANAGEMENT, L.P. | New Position | 715,307 | May 15, 2026 |
| EVENTIDE ASSET MANAGEMENT, LLC | New Position | 715,307 | May 15, 2026 |
| POINT72 ASSET MANAGEMENT, L.P. | Increased | 692,111 | May 15, 2026 |
| ADAR1 CAPITAL MANAGEMENT, LLC | Increased | 524,441 | May 18, 2026 |
| VELAN CAPITAL INVESTMENT MANAGEMENT LP | Increased | 512,160 | May 15, 2026 |
| BALYASNY ASSET MANAGEMENT L.P. | Increased | 465,792 | May 15, 2026 |
| WOODLINE PARTNERS LP | New Position | 457,441 | May 15, 2026 |
| UBS GROUP AG | Increased | 392,871 | May 5, 2026 |
Insider activity from SEC Form 4; institutional positioning from 13F filings · Latest filing Jun 9, 2026